Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
详细信息 查看全文
- 作者：Christina Pfirschke1 ; 7 ; Camilla Engblom1 ; 2 ; 7 ; Steffen Rickelt3 ; Virna Cortez-Retamozo1 ; Christopher Garris1 ; 2 ; Ferdinando Pucci1 ; Takahiro Yamazaki4 ; Vichnou Poirier-Colame4 ; Andita Newton1 ; Younes Redouane1 ; Yi-Jang Lin1 ; Gregory Wojtkiewicz1 ; Yoshiko Iwamoto1 ; Mari Mino-Kenudson5 ; Tiffany G. Huynh5 ; Richard O. Hynes3 ; Gordon J. Freeman6 ; Guido Kroemer4 ; Laurence Zitvogel4 ; Ralph Weissleder1 ; Mikael J. Pittet1 ; mpittet@mgh.harvard.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Immunity
- 出版年：2016
- 出版时间：16 February 2016
- 年：2016
- 卷：44
- 期：2
- 页码：343-354
- 全文大小：4740 K
文摘
- •
Kras/Trp53 mutant tumors lack CD8+ T cells and resist chemo- and immunotherapies
- •
Immunogenic chemotherapy elicits tumor T cell infiltration and controls cancer growth
- •
Tumor control requires CD8+ T cells, TLR4+ cells, and drug actions on cancer cells
- •
T cell influx sensitizes tumors to checkpoint inhibition and durably controls cancer
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |